151 related articles for article (PubMed ID: 29043431)
21. Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches.
Dorff TB; Kasparian S; Garg N; Liu S; Pal SK; Wong J; Dandapani S
J Clin Med; 2023 Mar; 12(5):. PubMed ID: 36902798
[TBL] [Abstract][Full Text] [Related]
22. [
Menendez MI; Moore RR; Abdel-Rasoul M; Wright CL; Fernandez S; Jackson RD; Knopp MV
Front Med (Lausanne); 2021; 8():725118. PubMed ID: 35096851
[TBL] [Abstract][Full Text] [Related]
23. Comparison of PET/CT and MRI in the Diagnosis of Bone Metastasis in Prostate Cancer Patients: A Network Analysis of Diagnostic Studies.
Liu F; Dong J; Shen Y; Yun C; Wang R; Wang G; Tan J; Wang T; Yao Q; Wang B; Li L; Mi J; Zhou D; Xiong F
Front Oncol; 2021; 11():736654. PubMed ID: 34671558
[TBL] [Abstract][Full Text] [Related]
24. Salvage therapy for prostate cancer after radical prostatectomy.
Zaorsky NG; Calais J; Fanti S; Tilki D; Dorff T; Spratt DE; Kishan AU
Nat Rev Urol; 2021 Nov; 18(11):643-668. PubMed ID: 34363040
[TBL] [Abstract][Full Text] [Related]
25. Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.
van der Bruggen W; Vriens D; Meier ME; Smit F; Winter EM; de Geus-Oei LF; Appelman-Dijkstra NM
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2980-e2994. PubMed ID: 33788944
[TBL] [Abstract][Full Text] [Related]
26. The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.
Abrams-Pompe RS; Fanti S; Schoots IG; Moore CM; Turkbey B; Vickers AJ; Walz J; Steuber T; Eastham JA
Eur Urol Oncol; 2021 Jun; 4(3):370-395. PubMed ID: 33272865
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study.
Donswijk ML; van Leeuwen PJ; Vegt E; Cheung Z; Heijmink SWTPJ; van der Poel HG; Stokkel MPM
BMC Cancer; 2020 Aug; 20(1):723. PubMed ID: 32758168
[TBL] [Abstract][Full Text] [Related]
28. Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography.
Hintz HM; Gallant JP; Vander Griend DJ; Coleman IM; Nelson PS; LeBeau AM
Clin Cancer Res; 2020 Sep; 26(18):4882-4891. PubMed ID: 32636317
[TBL] [Abstract][Full Text] [Related]
29. The Value of
Madsen C; Østergren P; Haarmark C
Diagnostics (Basel); 2020 May; 10(6):. PubMed ID: 32481743
[TBL] [Abstract][Full Text] [Related]
30. Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT.
van der Bruggen W; Hagelstein-Rotman M; de Geus-Oei LF; Smit F; Dijkstra PDS; Appelman-Dijkstra NM; Vriens D
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1527-1537. PubMed ID: 31875244
[TBL] [Abstract][Full Text] [Related]
31. Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.
Glumac PM; Gallant JP; Shapovalova M; Li Y; Murugan P; Gupta S; Coleman IM; Nelson PS; Dehm SM; LeBeau AM
Clin Cancer Res; 2020 Mar; 26(5):1054-1064. PubMed ID: 31732520
[TBL] [Abstract][Full Text] [Related]
32. Liquid Biopsy in Oligometastatic Prostate Cancer-A Biologist's Point of View.
Stelcer E; Konkol M; Głȩboka A; Suchorska WM
Front Oncol; 2019; 9():775. PubMed ID: 31475117
[TBL] [Abstract][Full Text] [Related]
33. Nuclear medicine: workplace monitoring and internal occupational exposure during a ventilation/perfusion single-photon emission tomography.
Martínez J; Baciu T; Artigues M; Danús M; Peñalver A; Aguilar C; Borrull F
Radiat Environ Biophys; 2019 Aug; 58(3):407-415. PubMed ID: 31139897
[TBL] [Abstract][Full Text] [Related]
34. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.
Zhou J; Gou Z; Wu R; Yuan Y; Yu G; Zhao Y
Skeletal Radiol; 2019 Dec; 48(12):1915-1924. PubMed ID: 31127357
[TBL] [Abstract][Full Text] [Related]
35. Imaging modalities in synchronous oligometastatic prostate cancer.
Futterer JJ; Surcel C; van den Bergh R; Borgmann H; Briganti A; Gandaglia G; Kretschmer A; Ost P; Sooriakumaran P; Tilki D; Valerio M; Ploussard G; De Visschere PJL; Tsaur I;
World J Urol; 2019 Dec; 37(12):2573-2583. PubMed ID: 30069582
[TBL] [Abstract][Full Text] [Related]
36.
Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
[TBL] [Abstract][Full Text] [Related]
37. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
38. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
39. A Prospective Study Comparing
Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
[TBL] [Abstract][Full Text] [Related]
40.
Langsteger W; Rezaee A; Pirich C; Beheshti M
Semin Nucl Med; 2016 Nov; 46(6):491-501. PubMed ID: 27825429
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
